Consider ordering for individuals with paraneoplastic encephalomyelitis, chorea, cerebellar degeneration, optic neuritis, and peripheral neuropathy. May aid in diagnosis of occult or recurrent tumor.
Semi-Quantitative Cell-Based Indirect Fluorescent Antibody
New York DOH Approval Status
Serum Separator Tube (SST) or Plain Red
Transfer 1 mL serum to an ARUP Standard Transport Tube. (Min: 0.25 mL)
Hemolyzed, contaminated, or severely lipemic specimens
Ambient: 48 hours; Refrigerated: 2 weeks; Frozen: 1 year
|CV2.1 Antibody IgG Screen by IFA||Less than 1:10|
CV2.1 antibodies aid in discriminating between chronic paraneoplastic neurological disorder (PND) and other inflammatory disorders of the nervous system. Anti-CV2.1 is associated with small-cell lung cancer and thymoma.
This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.
Laboratory Developed Test (LDT)
If CV2.1 Antibody IgG Screen by IFA is positive, then CV2.1 Antibody IgG Titer by IFA will be added. Additional charges apply.
86255; if reflexed, add 86256
|Component Test Code*||Component Chart Name||LOINC|
|2013959||CV2.1 Antibody IgG Screen by IFA||72504-4|
- Cerebellar degeneration
- Collapsin response-mediator protein 5
- Cranial neuropathy
- Peripheral neuropathy
- Vision loss